BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with poor outcomes.
• Limited treatment options exist for refractory PBL.
• PBL shares antigen expression with multiple myeloma (MM), including BCMA.

Purpose of the Study:

• To evaluate the efficacy of BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy in a patient with refractory PBL.
• To assess the safety and tolerability of BCMA CAR-T in this context.

Main Methods:

• Case report of an adolescent with multiply relapsed/refractory PBL post-allogeneic hematopoietic cell transplant.
• Administration of BCMA CAR-T therapy under emergency investigational new drug (eIND) protocol.
• Monitoring for treatment response, toxicity (CRS, ICANS, GVHD), and CAR-T cell expansion.

Main Results:

• The patient achieved a complete remission (CR) following BCMA CAR-T therapy.
• No recurrence of CRS, ICANS, or acute GVHD was observed.
• Sustained CR for over one year with detectable in vivo CAR-T cell expansion.

Conclusions:

• BCMA CAR-T therapy can induce durable remission in refractory PBL.
• This approach warrants further investigation for patients with limited therapeutic alternatives.
• BCMA CAR-T represents a potential immunotherapy for aggressive B-cell malignancies.